Company intelligence / Profile preview
Pionex Management Group Pharm
South Koreapionex.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Pionex Management Group Pharm has developed at least one approved drug, PG‑201, targeting IL‑1β and TNF‑α for osteoarthritis. The company also has several pending or investigational programs in arthritis and knee osteoarthritis. Clinical trial activity includes at least six trials with a focus on herbal medicines and anti-inflammatory mechanisms.
- Therapeutic areas
- Rheumatology
- Modalities
- Herbal medicineSmall molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Pionex Management Group Pharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pionex Management Group Pharm.